Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Type 2 Diabetes Clinical Trial

Official title:

Study of the Effects of Glutamine on Glycemia, Glucagon-like Peptide-1 (GLP-1) and Insulin Secretion in Man

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00673894
• Other study ID #: H07/059
• Status: Completed
• Phase: N/A
• Start date: April 2008
• Est. completion date: November 2014

Study information

• Verified date: February 2019
• Source: Garvan Institute of Medical Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.

Description:

In this study, we investigated the effect of glutamine, an amino acid, on glycemia and on GLP-1 and insulin in participants with type 2 diabetes. Preliminary data published by our group suggests that glutamine is a strong determinant of GLP-1 secretion in vitro. We tested the hypothesis that glutamine lowers postprandial blood glucose and investigated whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin modifies this effect.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: November 2014
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin)

Exclusion Criteria:

• Malabsorption, renal or liver disease, treatment with steroids

Related Conditions & MeSH terms

• Type 2 Diabetes

Intervention

Drug:
• Sitagliptin
Glutamine 30g +sitagliptin 100mg
• Placebo
Glutamine 30g +placebo (matching sitagliptin 100 mg)

Locations

Country	Name	City	State
Australia	Clinical Research Facility	Sydney	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Garvan Institute of Medical Research

Country where clinical trial is conducted

Australia, 

References & Publications (3)

Samocha-Bonet D, Chisholm DJ, Gribble FM, Coster AC, Carpenter KH, Jones GR, Holst JJ, Greenfield JR. Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. PLoS One. 2014 Nov — View Citation

Samocha-Bonet D, Chisholm DJ, Holst JJ, Greenfield JR. L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients. Nutrients. 2015 Mar 24;7(4):2101-8. doi: 10.3390/nu7042101. — View Citation

Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, Gribble FM, Holst JJ, Chisholm DJ, Greenfield JR. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr. 2011 Jul;141(7):1 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postprandial Glucose Area Under the Curve (AUC)	The area under the curve (AUC) of the postprandial glucose following a meal challenge	0 to 180 minutes
Secondary	Fructosamine	The blood concentration of the glycemic control marker fructosamine	4 weeks